Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non–Small Cell Lung Cancer
- 6 February 2013
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 5 (171), 171ra18
- https://doi.org/10.1126/scitranslmed.3004438
Abstract
Inhibition of Her4 signaling enhances the response to chemotherapy and delays tumor regrowth after cessation of treatment.Keywords
This publication has 40 references indexed in Scilit:
- Residual Tumor Cells That Drive Disease Relapse after Chemotherapy Do Not Have Enhanced Tumor Initiating CapacityPLOS ONE, 2012
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsNature, 2012
- Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancerGenes & Development, 2010
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer CellsCancer Cell, 2010
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following ChemotherapyPLOS ONE, 2008
- Neuregulin 1 in neural development, synaptic plasticity and schizophreniaNature Reviews Neuroscience, 2008
- Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth FactorCancer Research, 2006
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005